AlphAIAlphAI — Financial news for AI agents
sci-tech-today.comAUG 104 min read$LFMD

LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.

Original reporting
sci-tech-today.com
Published Aug 10, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate — source image
Source · sci-tech-today.com
Decision brief

The 30-second read

$LFMDBearishHigh
01

Why it matters

The quarter combined a revenue/EPS miss with a larger-than-expected reduction in full-year 2026 revenue and adjusted EBITDA range, prompting a sharp after-hours decline.

02

Market read

Traders are likely to focus on the guidance cut and the path to adjusted EBITDA breakeven, not just gross margin and subscriber growth.

03

What to watch

The article notes the transition away from compounded GLP-1s is near completion (95% of new Weight Management patients on branded GLP-1s), which may improve longer-term unit economics despite the near-term guidance reset.

Relevance 9/10Novelty 8/10Timing: after-hours reaction on Aug 10, 2026 earnings release

Background

LifeMD is shifting its revenue mix toward recurring subscriptions and branded GLP-1 therapies, with an in-house pharmacy and telehealth plus affiliated medical group.

Company-level read

Ticker impact

$LFMDBearishHigh confidence
Context

LifeMD reported Q2 2026 revenue of $47.3M and GAAP EPS loss of $0.16, missing consensus and cutting full-year 2026 guidance.

Expected impact

Bearish near-term bias; elevated volatility likely as traders digest the guidance reset and subscriber mix shift to branded GLP-1s.

Evidence & confidence

The article cites both the miss (revenue and EPS) and a material guidance reduction for 2026, alongside a 12.23% after-hours drop.

Market effects

Sector

Signals pressure on virtual-care profitability and the earnings sensitivity of GLP-1 transition economics for subscription-based telehealth models.

Regional

Primarily impacts US small-cap healthcare/telehealth sentiment; limited direct cross-region spillover implied.

Global

Low global relevance beyond the US virtual-care and GLP-1-adjacent investor cohort.

Counterpoint

What could challenge this read

Gross margin expanded to ~89% and subscribers rose to ~356,000, suggesting operating leverage could re-emerge if acquisition spending normalizes.

Key entities

  • company
    LifeMD, Inc.

    Nasdaq-listed virtual-care provider reporting Q2 2026 results and reduced 2026 guidance.

  • executive
    Justin Schreiber

    Chairman and CEO quoted on longer patient relationships and diversified acquisition model.

  • executive
    Atul Kavthekar

    CFO quoted on gross margin expansion drivers and pharmacy scaling.

Read at source← All news

Related articles

SEP 20
$LFMDMed

LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?

LifeMD (LFMD) partnered with AT&T to offer free virtual-health memberships to 29 million eligible customers in 11 states, with a nationwide expansion planned for 2027. The $19 monthly fee is waived, but services like visits and prescriptions remain payable. LifeMD aims to convert access into recurring demand for paid care, potentially reducing acquisition costs and benefiting from repeat consultations. The phased rollout allows for measuring enrollment and utilization before expansion.

yahoo.com2 min
SEP 16
$TMed

AT&T Waives $19 LifeMD Fee for 100 Million Wireless and Fiber Customers

AT&T is partnering with LifeMD to waive its $19 monthly membership fee for over 100 million wireless and fiber customers, making it the first carrier to bundle no-cost virtual healthcare access. The rollout begins in 11 states, with the rest following in January 2027. LifeMD (LFMD) provides telehealth services, and AT&T aims to enhance customer retention. AT&T's stock is valued at $29.03 per share, with projected slight earnings declines due to heavy capital spending.

kobaran.com3 min
AUG 13
$LFMDMedAI 9/10

LifeMD (LFMD) Q2 2026 Earnings Call Transcript

LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.

fool.com6 min
AUG 5
$LFMDMed

LifeMD Reports Second Quarter 2026 Results

LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. ● Approximately

SEC EDGAR 8-K6 min
OCT 23
$AALMedAI 8/10

American Airlines posts record Q3 revenue but fuel costs drive loss

American Airlines reported Q3 2026 revenue of $16.3B, up 19.3% YoY, but a net loss of $269M due to rising fuel costs. Premium and business travel drove revenue gains, with fuel expenses increasing $1.9B. The airline expects higher fuel prices to slow 2027 network growth and forecasts a Q4 adjusted loss of $0.50-$1.10 per share.

travelwires.com2 min